Niva Bupa Health

Why is Niva Bupa Health Insurance Company Ltd falling/rising?

As of 01-Sep, Niva Bupa Health Insurance Company Ltd's stock price is rising to 82.42, reflecting a 1.45% increase due to outperforming its sector, a trend reversal after declines, and strong long-term fundamentals, including significant growth in profits and sales. High institutional holdings further indicate investor confidence.

As of 01-Sep, Niva Bupa Health Insurance Company Ltd's stock price is rising, currently at 82.42, reflecting a change of 1.18 (1.45%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 3%, indicating a relative strength compared to its peers. Additionally, there has been a trend reversal as the stock has gained after two consecutive days of decline, suggesting a potential recovery in investor sentiment.<BR><BR>The stock reached an intraday high of Rs 83.76, which is a 3.1% increase, further demonstrating positive momentum. Despite a decrease in delivery volume by 45.6% against the 5-day average, the stock remains liquid enough for trading, which may support its price stability.<BR><BR>Moreover, the company shows strong long-term fundamental strength, with a remarkable 137.70% compound annual growth rate (CAGR) in operating profits and a healthy annual growth rate of 43.20% in net sales. Positive quarterly results, including a significant increase in profit after tax (PAT) and net sales, also contribute to the stock's upward movement. High institutional holdings at 28.25%, which have increased by 1.16% over the previous quarter, indicate confidence from larger investors who typically have more resources to analyze the company's fundamentals.<BR><BR>Overall, these factors collectively contribute to the rising stock price of Niva Bupa Health Insurance Company Ltd.

What does Niva Bupa Health do?

Niva Bupa Health Insurance Company Ltd provides health insurance services and reported net sales of 2,274 Cr and a net profit of 138 Cr for June 2026, with a market cap of INR 15,027 Cr. The company has a P/E ratio of 86.00 and a return on equity of 4.61%.

Overview:<BR>Niva Bupa Health Insurance Company Ltd operates in the insurance industry as a small-cap company, providing health insurance services.<BR><BR>History:<BR>The company was originally incorporated as Max Bupa Health Insurance Limited in 2008. It received its Certificate for Commencement of Business on December 23, 2008. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 2,274 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 138 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 15,027 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 86.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 4.61% <BR>Price to Book: 4.02 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Niva Bupa Health?

Niva Bupa Health's peers include HDFC Life, ICICI Lombard, Max Financial, and Star Health, among others. It has excellent growth but average management risk, with a 1-year return of -0.26%, better than Medi Assist but worse than New India Assura's 1.48%.

Peers: The peers of Niva Bupa Health are HDFC Life Insur., ICICI Lombard, ICICI Pru Life, General Insuranc, Max Financial, Star Health Insu, New India Assura, Go Digit General, and Medi Assist Ser.<BR><BR>Quality Snapshot: Excellent management risk is observed at ICICI Lombard and Go Digit General, while Good management risk is found at General Insuranc and Medi Assist Ser. Average management risk is present at HDFC Life Insur., ICICI Pru Life, Max Financial, Star Health Insu, and Niva Bupa Health, and the rest. Below Average management risk is noted at New India Assura. In terms of Growth, Excellent growth is seen at Niva Bupa Health, while Average growth is observed at HDFC Life Insur., ICICI Lombard, General Insuranc, and Go Digit General, and the rest. Below Average growth is noted at ICICI Pru Life, Max Financial, Star Health Insu, and New India Assura.<BR><BR>Return Snapshot: New India Assura has the highest 1-year return at 1.48%, while Medi Assist Ser. has the lowest at -34.99%. Niva Bupa Health's 1-year return is -0.26%, which is better than Medi Assist Ser. but worse than New India Assura. Additionally, the six-month return is negative for HDFC Life Insur., ICICI Lombard, ICICI Pru Life, Max Financial, Go Digit General, and Medi Assist Ser.

How big is Niva Bupa Health?

As of 31st August, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,027.00 Cr, with recent Net Sales of 7265.52 Cr and a Net Profit of 174.25 Cr. The company reported Shareholder's Funds of 3,786.31 Cr and Total Assets of 11,241.43 Cr for March 2026.

As of 31st August, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,027.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Niva Bupa reported Net Sales of 7265.52 Cr and a Net Profit of 174.25 Cr.<BR><BR>For the reporting period of March 2026, the company had Shareholder's Funds amounting to 3,786.31 Cr and Total Assets of 11,241.43 Cr.

Which are the latest news on Niva Bupa Health?

Are Niva Bupa Health Insurance Company Ltd latest results good or bad?

Niva Bupa Health Insurance Company's Q1 FY27 results are generally positive, with a 92.93% year-on-year net profit increase to ₹137.80 crores and a 28.56% revenue growth. However, a 13.54% sequential profit decline and a below-average return on equity indicate areas for improvement.

Niva Bupa Health Insurance Company Ltd's latest results for Q1 FY27 can be considered good overall, despite some mixed signals. The company reported a net profit of ₹137.80 crores, which is a remarkable increase of 92.93% year-on-year. Additionally, revenue grew by 28.56% to ₹2,273.72 crores, indicating strong top-line momentum.<BR><BR>The operating margin improved to 8.10%, up from 5.55% in the same quarter last year, reflecting better operational efficiency and cost management. However, it's worth noting that the net profit decreased by 13.54% compared to the previous quarter, which raises some concerns about sequential performance.<BR><BR>While the company has demonstrated significant revenue growth and improved profitability metrics, its return on equity (ROE) of 4.56% remains below industry averages, indicating challenges in capital efficiency. This aspect could be a concern for investors looking for strong returns on their investments.<BR><BR>In summary, while Niva Bupa's quarterly results show strong growth and operational improvements, the decline in sequential profit and lower ROE suggest that there are still areas for the company to address. Overall, the results reflect a positive trajectory, but caution is warranted regarding sustainability and capital efficiency moving forward.

Should I buy, sell or hold Niva Bupa Health Insurance Company Ltd?

When is the next results date for Niva Bupa Health Insurance Company Ltd?

The next results date for Niva Bupa Health Insurance Company Ltd is July 30, 2026.

The next results date for Niva Bupa Health Insurance Company Ltd is scheduled for July 30, 2026.

Is Niva Bupa Health technically bullish or bearish?

As of November 28, 2025, Niva Bupa Health's technical stance is bearish due to negative indicators like a bearish MACD and moving averages, despite a mildly bullish signal from Dow Theory.

As of 28 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Niva Bupa Health is bearish, with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands and moving averages on the daily timeframe, and a bearish KST on the weekly. Although the Dow Theory indicates a mildly bullish signal on the weekly, it is outweighed by the overall bearish indicators. The stock has underperformed against the Sensex year-to-date and over the past year, further supporting the bearish outlook.

How has been the historical performance of Niva Bupa Health?

Niva Bupa Health experienced significant growth from March 2024 to March 2025, with net sales rising to 4,894.46 Cr and profit after tax increasing to 213.52 Cr, while total assets grew to 9,760.16 Cr. The company improved its operating profit margin to 1.19% and enhanced cash flow from operating activities to 1,654.00 Cr.

Answer:<BR>The historical performance of Niva Bupa Health shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Niva Bupa Health's net sales increased from 3,811.25 Cr in March 2024 to 4,894.46 Cr in March 2025, while other operating income rose from 304.22 Cr to 479.82 Cr, leading to a total operating income of 5,374.28 Cr, up from 4,115.47 Cr. Total expenditure, excluding depreciation, also increased to 5,316.18 Cr from 4,254.40 Cr, with employee costs rising slightly and manufacturing expenses significantly increasing from 3,000.37 Cr to 4,061.10 Cr. The company turned around its operating profit, achieving 213.52 Cr in March 2025 compared to 81.85 Cr in March 2024, with a notable improvement in operating profit margin from -3.65% to 1.19%. Profit after tax also saw a substantial increase from 81.85 Cr to 213.52 Cr, resulting in a PAT margin growth from 2.15% to 4.36%. On the balance sheet, total assets grew from 6,191.86 Cr to 9,760.16 Cr, driven by an increase in non-current investments from 5,458.23 Cr to 8,175.08 Cr. Shareholder's funds rose significantly from 2,982.62 Cr to 3,776.22 Cr, while total liabilities increased to 9,760.16 Cr from 6,191.86 Cr. Cash flow from operating activities improved to 1,654.00 Cr from 812.00 Cr, although cash flow from investing activities worsened to -2,347.00 Cr from -1,881.00 Cr. The closing cash and cash equivalents increased to 220.00 Cr from 142.00 Cr, reflecting a positive cash flow trend.

Is Niva Bupa Health overvalued or undervalued?

As of November 27, 2024, Niva Bupa Health is considered very expensive and overvalued, with a PE ratio of 71.14 and significant underperformance at -0.62% year-to-date compared to the Sensex's 5.54%.

As of 27 November 2024, the valuation grade for Niva Bupa Health has moved from does not qualify to very expensive. The company is currently considered overvalued, with a PE ratio of 71.14, an EV to EBITDA ratio of 263.82, and a Price to Book Value of 7.37. These metrics significantly exceed those of its peers, such as Life Insurance with a PE ratio of 12.54 and Bajaj Finance Ltd. at 35.01, indicating a stark contrast in valuation.<BR><BR>In comparison to the broader market, Niva Bupa Health has underperformed, with a year-to-date return of -0.62% against the Sensex's 5.54%. This underperformance, coupled with its high valuation ratios, reinforces the conclusion that the company is overvalued in the current market environment.

Who are the top shareholders of the Niva Bupa Health?

The top shareholders of Niva Bupa Health are Bupa Singapore Holdings Pte Ltd with 55.98%, followed by foreign institutional investors at 8.9%, mutual funds at 2.68%, and individual investors at 4.23%. There are no pledged promoter holdings, reflecting strong promoter commitment.

The top shareholders of Niva Bupa Health include Bupa Singapore Holdings Pte Ltd, which holds a significant 55.98% of the company. The majority of the remaining shares are held by mutual funds, which account for 2.68% across 14 schemes, and foreign institutional investors (FIIs), who hold 8.9% through 42 different entities. Additionally, individual investors collectively own 4.23% of the shares. Notably, there are no pledged promoter holdings, indicating a strong commitment from the promoters.

Has Niva Bupa Health declared dividend?

No Dividend History Available